Native GLP-1 and GLP-1 analogues are reported to have several significant cardiovascular effects providing the opportunity to address the multifactorial issues involved in increased mortality and morbidity associated with T2D as well as in patients with cardiac disease and no diabetes [8]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.